Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Solriamfetol in Excessive Sleepiness Associated With Shift Work Disorder
NCT06568367Phase 3Recruiting
- Sponsor
- Axsome Therapeutics, Inc.
- Start
- Aug 2024
- Primary completion
- Dec 2026
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
A Phase 3 trial of solriamfetol in shift work sleep disorder (SWSD), Hypersomnia (HS), sponsored by Axsome Therapeutics, Inc.. Started Aug 2024; status: recruiting.
02
Drugs
solriamfetol
03
Conditions
shift work sleep disorder (SWSD)Hypersomnia (HS)
Beyond the preview
Go deeper on NCT06568367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06568367.